BusinessVoyager Therapeutics Selects Lead Clinical Candidate for Huntington’s DiseaseBy Nasdaq OMXJun 1, 2017, 11:27 AM UTC
BusinessVoyager Therapeutics Selects Lead Clinical Candidate for Huntington’s DiseaseBy Nasdaq OMXJun 1, 2017, 11:27 AM UTC
BusinessVoyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s DiseaseBy Nasdaq OMXSep 12, 2016, 11:05 AM UTC
BusinessVaccinex, Inc. Announces Continuation of the SIGNAL Clinical TrialBy Nasdaq OMXSep 9, 2016, 1:45 PM UTC
BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy ActivitiesBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
